(Reuters) – Bristol-Myers Pharmaceuticals (NYSE: Squibb Co and .) Abbvie Company (NYSE: 🙂 told California officials they plan to cut as many as 360 jobs there in unrelated moves, according to notices to the state announced earlier this week.
Bristol Myers plans to cut as many as 261 jobs at two different San Diego locations, according to filings. A Bristol-Myers spokesperson said the job cuts follow the company’s $4.1 billion acquisition of drug developer Turning Point Therapeutics (NASDAQ:), which closed in August.
“All new employees have received retention packages associated with continuing service to BMS for a period of time and have been encouraged to apply for long-term positions at BMS after their retention period has ended,” the spokesperson said in an email.
Separately, AbbVie plans to cut up to 99 jobs in Irvine, California, the company told the state. The company did not respond to a request for comment.
The job cuts were previously reported by Endpoints News.